U.S. Wireless Telecom Stock News

NasdaqGM:IDN
NasdaqGM:IDNSoftware

Intellicheck (IDN) Q4 EPS Breakthrough Tests High Growth Narrative Against 87.9x P/E

Intellicheck (IDN) has rounded out FY 2025 with fourth quarter revenue of about US$6.6 million and basic EPS of roughly US$0.08, alongside trailing twelve month revenue of US$22.7 million and EPS of about US$0.07 that reflect a move into positive net income of around US$1.3 million over the year. The company has seen quarterly revenue progress from US$4.9 million in Q1 2025 to US$6.6 million in Q4 2025, with EPS shifting from a small loss of roughly US$0.02 per share early in the year to a...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Warner Bros. Discovery’s US$110b Sale To Paramount Skydance Reframes Shareholder Upside

Warner Bros. Discovery (NasdaqGS:WBD) has agreed to be acquired by Paramount Skydance in a cash and stock deal valued at $110b. The transaction includes a record-breaking golden parachute package for CEO David Zaslav as part of the change in control. The deal follows a period of awards recognition for Warner Bros.' recent film slate and is expected to reshape competition among major studios. For investors tracking NasdaqGS:WBD, this $110b agreement comes after a very strong 1 year share...
NasdaqGS:LIN
NasdaqGS:LINChemicals

Linde’s Oshkosh Plant And What It Means For Midwest Growth

Linde plans to build a new industrial gases facility in Oshkosh, Wisconsin. The project is intended to expand supply capacity for industrial customers across the Midwest. The development marks a further investment in regional infrastructure for NasdaqGS:LIN. Linde, trading on NasdaqGS:LIN, is moving ahead with construction of a new industrial gases facility in Oshkosh, Wisconsin, adding to its US footprint. The company’s shares most recently closed at $488.15, with a return of 13.8% year to...
NYSE:GPGI
NYSE:GPGITech

Is GPGI (GPGI) Share Price Outrunning Fundamentals After Recent Volatility?

If you are wondering whether GPGI is attractively priced or already reflecting a lot of optimism, the current share price at US$17.06 raises some useful questions about what you are really paying for. Recent returns are mixed, with the stock up 3.3% over the last week but showing a 27.4% decline over 30 days, an 8.6% decline year to date, and gains of 51.0% over 1 year, 191.8% over 3 years, and 114.8% over 5 years. These moves sit against a backdrop of ongoing coverage that keeps GPGI on...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

LivaNova’s Aura6000 FDA Win Reshapes Obstructive Sleep Apnea Opportunity

FDA grants premarket approval to LivaNova's aura6000 System for adult patients with moderate to severe Obstructive Sleep Apnea who do not benefit from standard therapies. The system uses proximal hypoglossal nerve stimulation and is supported by clinical trial data showing meaningful outcomes, including in harder to treat patient groups. LivaNova (NasdaqGS:LIVN) also discloses work on a next generation, MRI compatible version of the aura6000 with additional features. LivaNova, listed on...
NasdaqGM:RICK
NasdaqGM:RICKHospitality

RCI Hospitality Holdings (RICK) One Off US$5.2m Loss Tests Bullish Earnings Narrative

RCI Hospitality Holdings (RICK) FY 2025 earnings at a glance RCI Hospitality Holdings (RICK) has just posted its FY 2025 numbers with Q4 revenue of US$70.9 million and a basic EPS loss of US$0.63, set against trailing 12 month EPS of US$1.23 on revenue of US$279.4 million and earnings growth of 259.1% for the period. Over recent quarters, revenue has moved from US$73.2 million in Q4 2024 to US$71.5 million in Q1 2025, US$65.9 million in Q2, US$71.1 million in Q3 and US$70.9 million in Q4,...
NYSE:NOG
NYSE:NOGOil and Gas

Is It Too Late To Consider Northern Oil and Gas (NOG) After Strong 2024 Share Gains?

If you are wondering whether Northern Oil and Gas at around US$28.84 is offering fair value or a potential mismatch between price and underlying worth, you are not alone. The stock has recent returns of 4.8% over 7 days, 5.4% over 30 days, 31.0% year to date and 2.4% over 1 year, which naturally raises questions about how much is already reflected in the price. Recent coverage has focused on Northern Oil and Gas in the context of its role within the broader energy sector and its position as...
NasdaqCM:MVST
NasdaqCM:MVSTMachinery

A Look At Microvast Holdings (MVST) Valuation After Expanded Iveco Deal Earnings And Going Concern Warning

Microvast Holdings (MVST) is back in focus after reaffirming and expanding its long running battery partnership with Iveco Group in Europe, alongside releasing 2025 results, 2026 guidance, and an auditor warning on going concern risks. See our latest analysis for Microvast Holdings. Despite a series of material updates including the expanded Iveco partnership, 2025 results, 2026 guidance and the going concern warning, Microvast’s recent share price performance has been weak. The 30 day share...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Is It Time To Reassess Viridian Therapeutics (VRDN) After Its Strong 1-Year Share Price Run?

If you are wondering whether Viridian Therapeutics at around US$26.98 is offering good value or asking too much, you are in the right place. The stock has recently seen mixed returns, with a 7 day move of 5.9% decline and a 30 day return of 4.0% decline, while still sitting on a 76.8% gain over the past year and 12.1% decline year to date. Recent news coverage has focused on Viridian Therapeutics as a biotech name that continues to attract attention from investors watching the sector. This...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

A Look At TransMedics Group (TMDX) Valuation After Share Pullback And Insider Selling Reports

TransMedics Group (TMDX) is drawing attention after a recent share pullback, with reports of insider selling by senior executives and directors coinciding with continued pressure on the stock, despite generally supportive analyst commentary. See our latest analysis for TransMedics Group. The recent weakness in TransMedics Group’s share price, including a 14.28% 1 month share price return decline and a 7.16% negative year to date share price return, sits against a much stronger 64.95% 1 year...
NYSE:GEV
NYSE:GEVElectrical

GE Vernova’s SMR Role Deepens US Japan Nuclear And Service Outlook

GE Vernova and Hitachi have been selected to supply BWRX-300 small modular reactors for a new US Japan nuclear program. The reactors are planned for deployment in Tennessee and Alabama as part of a wider $40b bilateral investment initiative. The selection positions GE Vernova at the center of a high profile cross border nuclear buildout focused on SMR technology. For investors watching NYSE:GEV, this project ties the company’s nuclear capabilities to a sizeable capital program that goes...
NYSE:HPE
NYSE:HPETech

Is Hewlett Packard Enterprise (HPE) Offering Value After Juniper Deal Scrutiny And Recent Price Weakness

Wondering whether Hewlett Packard Enterprise at around US$21.69 is offering genuine value or just headline appeal? This article breaks down what the current price might be implying about the business. The stock has recent returns of 0.5% over 7 days and 0.6% over 30 days, set against a year to date return of a 10.3% decline, and gains of 37.7% over 1 year, 64.4% over 3 years and 55.8% over 5 years. Recent coverage of Hewlett Packard Enterprise has focused on how investors are reassessing...
NYSE:BOBS
NYSE:BOBSSpecialty Retail

Is Bob's Discount Furniture (BOBS) Pricing Error Or Opportunity After Recent Share Price Slump

Wondering whether Bob's Discount Furniture is a bargain or a value trap at around US$12.49? This article breaks down what the current price might be implying about the business. The stock has seen sharp recent moves, with a 7 day return of an 18.9% decline and a 30 day return of a 37.2% decline, while the year to date return sits at a 26.6% decline. These swings have put Bob's Discount Furniture back on the radar for investors who are reassessing what they are willing to pay for retailers...
NasdaqGS:CPRT
NasdaqGS:CPRTCommercial Services

Is Copart (CPRT) Offering A Fresh Opportunity After A 39% One Year Share Price Slide

If you are wondering whether Copart's share price around US$32.86 is starting to look appealing or still has more room to fall, you are not alone. The stock has seen a 3.6% decline over the last week, a 12.7% decline over the past month, and a 13.0% decline year to date, adding to a 38.7% decline over the past year that may be changing how investors view its potential and risk. Recent coverage has focused on Copart's share price performance and how current levels compare with longer term...
NYSE:ESI
NYSE:ESIChemicals

Is It Time To Reassess Element Solutions (ESI) After Recent Materials Sector Re Rating?

To understand whether Element Solutions might still offer value at its recent price, you need to see how its fundamentals compare with what the market is currently paying. Over shorter periods, the stock has been mixed, with a 0.2% return over the last week, a 7.9% decline over the last month, a 19.7% gain year to date and a 24.5% return over the last year, alongside 75.2% and 78.7% returns across the past 3 and 5 years respectively. Recent news flow has highlighted Element Solutions in the...
NYSE:REXR
NYSE:REXRIndustrial REITs

A Look At Rexford Industrial Realty (REXR) Valuation After Recent Share Price Weakness

Rexford Industrial Realty stock performance snapshot Rexford Industrial Realty (REXR) has drawn attention after a stretch of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months and year as investors reassess industrial REIT exposure. See our latest analysis for Rexford Industrial Realty. With the latest share price at US$33.97, Rexford Industrial Realty’s recent 30 day share price return of 8.73% decline and 90 day share price return of...
NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

Is It Too Late To Consider LeMaitre Vascular (LMAT) After Its Recent Share Price Surge?

If you are wondering whether LeMaitre Vascular at around US$106 a share still offers value, you are not alone. A closer look at what that price really reflects can be useful. The stock has returned 17.3% over the last 30 days, 32.6% year to date and 28.5% over the past year, which may signal that expectations and perceived risk are shifting. Recent attention on LeMaitre Vascular has centered on how the company is positioned within medical devices and vascular care solutions, as investors...
NYSE:TXT
NYSE:TXTAerospace & Defense

Textron’s Mine Countermeasure Role Opens New Defense Growth Question For Investors

Textron (NYSE:TXT) has emerged as a key supplier of autonomous mine countermeasure systems for operations in the Strait of Hormuz. The company is supplying unmanned mine clearing technology as maritime security concerns in the region increase. This defense contract activity adds a new driver tied to naval and maritime security demand, separate from prior aviation and helicopter orders. For investors tracking NYSE:TXT, this shift into autonomous mine countermeasure systems comes with the...
NYSE:DHT
NYSE:DHTOil and Gas

DHT Holdings (DHT) Margin Strength Challenges Bearish Revenue Concerns In FY 2025 Results

DHT Holdings (DHT) has wrapped up FY 2025 with fourth quarter revenue of US$144.2 million and basic EPS of US$0.41, while trailing twelve month figures sit at US$551.3 million of revenue and EPS of US$1.31, underpinned by earnings growth of 16.4% over the last year. Over recent periods, quarterly revenue has moved between US$123.0 million and US$145.8 million, with basic EPS ranging from US$0.22 to US$0.41. Trailing net profit margin has improved from 31.7% to 38.3%, setting the stage for...
NYSE:ETR
NYSE:ETRElectric Utilities

Entergy Community Efforts Add Context For Dividend And Valuation Story

Entergy highlighted its support for workforce development and community resilience at the Dress for Success New Orleans event. Company leaders and employees participated in the event, underscoring involvement in local career readiness efforts. For investors watching Entergy (NYSE:ETR), this kind of community engagement sits alongside a share price of $99.9 and a value score of 3. The stock has seen a 6.4% return year to date and a 22.4% return over the past year, which gives added context...
NasdaqGS:ACLS
NasdaqGS:ACLSSemiconductor

Axcelis Targets China With Purion Launch And CS Asia Spotlight

Axcelis Technologies (NasdaqGS: ACLS) will serve as the Diamond Sponsor of the Compound Semiconductor Asia Conference (CS Asia) 2026 during SEMICON China. The company plans to launch its next generation Purion Power Series+ Platform for chipmakers in China at the event. Axcelis CEO Mary Puma is scheduled to deliver a keynote address to industry participants and customers. Axcelis Technologies focuses on ion implantation and related processing equipment for the semiconductor sector, with...
NYSE:GSL
NYSE:GSLShipping

Global Ship Lease Shelf Plan And Report Highlight Fleet Growth And Valuation

Global Ship Lease (NYSE:GSL) files a new US$229 million Shelf Registration. The company also publishes its 2025 Annual Report, covering recent fleet acquisitions and charter activity. Both filings offer fresh detail on capital plans, fleet growth, and charter coverage for the year ahead. Global Ship Lease focuses on owning and chartering containerships, so its funding plans and fleet moves matter directly for earnings power and balance sheet risk. The new US$229 million Shelf Registration...
NasdaqGS:TRMB
NasdaqGS:TRMBSoftware

Does Geospatial Weakness And Acquisition Needs Change The Bull Case For Trimble (TRMB)?

In recent days, commentary on Trimble has highlighted that its geospatial technology business has faced a 2.8% annual revenue decline over the past two years, as customers postponed purchases and organic growth weakened. This pattern, alongside higher capital requirements and softer free cash flow margins, raises questions about whether Trimble will need acquisitions to reinvigorate its core operations. We’ll now examine how Trimble’s revenue declines and softer organic growth might affect...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

SELLAS Life Sciences’ AML Pipeline Adds Key Clinical Checkpoints For Investors

SELLAS Life Sciences Group (NasdaqCM:SLS) has begun a Phase 2 trial of SLS009 in first line acute myeloid leukemia (AML), targeting high risk patient subgroups. The company plans to present new preclinical data for SLS009, including activity in difficult to treat AML mutations, at an upcoming AACR meeting. SELLAS is progressing toward the final analysis of the Phase 3 REGAL trial of its GPS cancer vaccine in AML, with trial oversight ongoing and positive trends in patient outcomes...